Open AccessP520: PHASE 1/2 STUDY OF SEL24/MEN1703, A FIRST‐IN‐CLASS DUAL PIM/FLT3 KINASE INHIBITOR, IN PATIENTS WITH IDH1/2‐MUTATED ACUTE MYELOID LEUKEMIA: THE DIAMOND‐01 TRIAL.
Author(s) -
Martinelli G.,
Santoro A.,
GambacortiPasserini C.,
Vives Polo S.,
Solomon S. R.,
Mukherjee S.,
LechMaranda E.,
Yair Levy M.,
Wierzbowska A.,
CalbachoRobles M.,
Marconi G.,
Benedetta Giannini M.,
Cano I.,
Torres Miñana L.,
AcuñaCruz E.,
Angelosanto N.,
Galleu A.,
Baldini S.,
Blotta S.,
Ravandi F.,
Montesinos P.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000844968.45342.3d
Subject(s) - medicine , clinical endpoint , myeloid leukemia , adverse effect , concomitant , oncology , cohort , idh1 , gastroenterology , clinical trial , mutation , biology , biochemistry , gene